APA (7th ed.) Citation

Bruggen, F. H. v., & Luijendijk, H. J. Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Bruggen, F. H. van, and H. J. Luijendijk. Type 2 MI a Legitimate Efficacy Endpoint in Cardiovascular Trials? A Critical Appraisal. Frontiers Media S.A.

MLA (9th ed.) Citation

Bruggen, F. H. van, and H. J. Luijendijk. Type 2 MI a Legitimate Efficacy Endpoint in Cardiovascular Trials? A Critical Appraisal. Frontiers Media S.A.

Warning: These citations may not always be 100% accurate.